436 related articles for article (PubMed ID: 11698456)
41. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
42. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz J; Brück J; Lenz J; Knop J; Tüting T
Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
[TBL] [Abstract][Full Text] [Related]
43. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
[TBL] [Abstract][Full Text] [Related]
44. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.
Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF
Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766
[TBL] [Abstract][Full Text] [Related]
45. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
46. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
Michaeli Y; Denkberg G; Sinik K; Lantzy L; Chih-Sheng C; Beauverd C; Ziv T; Romero P; Reiter Y
J Immunol; 2009 May; 182(10):6328-41. PubMed ID: 19414786
[TBL] [Abstract][Full Text] [Related]
47. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
[TBL] [Abstract][Full Text] [Related]
49. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
[TBL] [Abstract][Full Text] [Related]
50. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
51. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
52. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
53. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells.
Bullock TN; Mullins DW; Engelhard VH
J Immunol; 2003 Feb; 170(4):1822-9. PubMed ID: 12574347
[TBL] [Abstract][Full Text] [Related]
54. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
55. Decline in MHC class I expression with increasing thickness of cutaneous melanomas in standard-strain transgenic mouse models.
Milling SW; Silvers WK; Sai T; Mintz B
Melanoma Res; 2002 Jun; 12(3):221-30. PubMed ID: 12140378
[TBL] [Abstract][Full Text] [Related]
56. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.
Lotz C; Ferreira EA; Drexler I; Mutallib SA; Huber C; Sutter G; Theobald M
Int J Cancer; 2004 Feb; 108(4):571-9. PubMed ID: 14696122
[TBL] [Abstract][Full Text] [Related]
57. Optimizing T-cell receptor avidity with somatic hypermutation.
Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Eisenbach L
Int J Cancer; 2019 Nov; 145(10):2816-2826. PubMed ID: 31381134
[TBL] [Abstract][Full Text] [Related]
58. Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients.
Palermo B; Campanelli R; Mantovani S; Lantelme E; Manganoni AM; Carella G; Da Prada G; della Cuna GR; Romagne F; Gauthier L; Necker A; Giachino C
Eur J Immunol; 2001 Feb; 31(2):412-20. PubMed ID: 11180105
[TBL] [Abstract][Full Text] [Related]
59. A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.
Yu Q; Zhang L; Ouyang L; Gong Y; Liang Z; Shen G; Weng X; Wu X
Immunogenetics; 2013 Mar; 65(3):173-84. PubMed ID: 23233149
[TBL] [Abstract][Full Text] [Related]
60. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
